These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 17913718)

  • 1. Comment on: Impact of antibiotic resistance and of adequate empirical antibiotic treatment in the prognosis of patients with Escherichia coli bacteraemia.
    Blot S; Vandijck D; Vandewoude K; Depuydt P; Vogelaers D; Peleman R
    J Antimicrob Chemother; 2007 Dec; 60(6):1402. PubMed ID: 17913718
    [No Abstract]   [Full Text] [Related]  

  • 2. Impact of antibiotic resistance and of adequate empirical antibiotic treatment in the prognosis of patients with Escherichia coli bacteraemia.
    Peralta G; Sánchez MB; Garrido JC; De Benito I; Cano ME; Martínez-Martínez L; Roiz MP
    J Antimicrob Chemother; 2007 Oct; 60(4):855-63. PubMed ID: 17644532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of 4758 Escherichia coli bacteraemia episodes: predictive factors for isolation of an antibiotic-resistant strain and their impact on the outcome.
    Ortega M; Marco F; Soriano A; Almela M; Martínez JA; Muñoz A; Mensa J
    J Antimicrob Chemother; 2009 Mar; 63(3):568-74. PubMed ID: 19126669
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical consequences of increased ciprofloxacin and gentamicin resistance in patients with Escherichia coli bacteraemia in the Netherlands.
    Cranendonk DR; van der Valk M; Langenberg ML; van der Meer JT
    Scand J Infect Dis; 2012 May; 44(5):363-8. PubMed ID: 22200089
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Piperacillin-resistant Escherichia coli bacteraemia: relation to empiric therapy and clinical outcome.
    Andersen NF; Møller J; Peterslund NA
    Scand J Infect Dis; 2005; 37(2):90-5. PubMed ID: 15764199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical outcomes and therapeutic options of bloodstream infections caused by extended-spectrum beta-lactamase-producing Escherichia coli.
    Metan G; Zarakolu P; Cakir B; Hascelik G; Uzun O
    Int J Antimicrob Agents; 2005 Sep; 26(3):254-7. PubMed ID: 16122910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical significance of healthcare-associated infections in community-onset Escherichia coli bacteraemia.
    Cheong HS; Kang CI; Kwon KT; Heo ST; Wi YM; Kim ES; Lee JS; Ko KS; Chung DR; Lee NY; Song JH; Peck KR
    J Antimicrob Chemother; 2007 Dec; 60(6):1355-60. PubMed ID: 17923453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A matched prospective cohort study on Staphylococcus aureus and Escherichia coli bloodstream infections: extended perspectives beyond resistance.
    Berger J; Diab-Elschahawi M; Blacky A; Pernicka E; Spertini V; Assadian O; Koller W; Aichberger KJ
    Am J Infect Control; 2010 Dec; 38(10):839-45. PubMed ID: 20650546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of higher minimum inhibitory concentrations of quaternary ammonium compounds in clinical E. coli isolates on antibiotic susceptibilities and clinical outcomes.
    Buffet-Bataillon S; Branger B; Cormier M; Bonnaure-Mallet M; Jolivet-Gougeon A
    J Hosp Infect; 2011 Oct; 79(2):141-6. PubMed ID: 21807440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ceftriaxone treatment failure in cephalosporin-susceptible Escherichia coli bacteraemia.
    Papanicolas LE; Bell JM; Weldhagen GF; Bastian I
    Int J Antimicrob Agents; 2013 Mar; 41(3):298-9. PubMed ID: 23312600
    [No Abstract]   [Full Text] [Related]  

  • 11. Modelling the impact of antibiotic use on antibiotic-resistant Escherichia coli using population-based data from a large hospital and its surrounding community.
    Vernaz N; Huttner B; Muscionico D; Salomon JL; Bonnabry P; López-Lozano JM; Beyaert A; Schrenzel J; Harbarth S
    J Antimicrob Chemother; 2011 Apr; 66(4):928-35. PubMed ID: 21393172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of risk factors for the acquisition of bloodstream infections with extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species in the intensive care unit; antibiotic management and clinical outcome.
    Cordery RJ; Roberts CH; Cooper SJ; Bellinghan G; Shetty N
    J Hosp Infect; 2008 Feb; 68(2):108-15. PubMed ID: 18063198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in Escherichia coli resistance patterns during and after antibiotic therapy: a longitudinal study among outpatients in Germany.
    Raum E; Lietzau S; von Baum H; Marre R; Brenner H
    Clin Microbiol Infect; 2008 Jan; 14(1):41-8. PubMed ID: 18005177
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [52-year-old patient with persistent fever despite adequate antibiotic therapy. Infected venous thrombosis].
    Kaasch A; Seifert H
    Dtsch Med Wochenschr; 2010 Jun; 135(23):1175-6. PubMed ID: 20514597
    [No Abstract]   [Full Text] [Related]  

  • 15. Neonatal Escherichia coli Bloodstream Infections: Clinical Outcomes and Impact of Initial Antibiotic Therapy.
    Bergin SP; Thaden JT; Ericson JE; Cross H; Messina J; Clark RH; Fowler VG; Benjamin DK; Hornik CP; Smith PB;
    Pediatr Infect Dis J; 2015 Sep; 34(9):933-6. PubMed ID: 26065862
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence, risk factors and outcomes of Escherichia coli bloodstream infections in a large Canadian region.
    Laupland KB; Gregson DB; Church DL; Ross T; Pitout JD
    Clin Microbiol Infect; 2008 Nov; 14(11):1041-7. PubMed ID: 19040476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence and clinical impact of extended-spectrum-beta-lactamase (ESBL) production and fluoroquinolone resistance in bloodstream infections caused by Escherichia coli in patients with hematological malignancies.
    Trecarichi EM; Tumbarello M; Spanu T; Caira M; Fianchi L; Chiusolo P; Fadda G; Leone G; Cauda R; Pagano L
    J Infect; 2009 Apr; 58(4):299-307. PubMed ID: 19272650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fluoroquinolone-resistant Escherichia coli: food for thought.
    Collignon P; Angulo FJ
    J Infect Dis; 2006 Jul; 194(1):8-10. PubMed ID: 16741876
    [No Abstract]   [Full Text] [Related]  

  • 19. Peptide nucleic acid antisense oligomer as a therapeutic strategy against bacterial infection: proof of principle using mouse intraperitoneal infection.
    Tan XX; Actor JK; Chen Y
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3203-7. PubMed ID: 16048926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Predictive factors of ESBL versus non-ESBL Escherichia coli bacteraemia and influence of resistance on the mortality of the patients].
    García Hernández A; García-Vázquez E; Gómez Gómez J; Canteras M; Hernandez-Torres A; Ruiz Gómez J
    Med Clin (Barc); 2011 Jan; 136(2):56-60. PubMed ID: 20673680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.